Our Mission
The National Hemophilia Foundation (NHF) Central Ohio Chapter is dedicated to finding cures for inheritable blood disorders and addressing and preventing the complications of these disorders through research, education, and advocacy enabling people and families to thrive.
Our Mission ... In Action
-
Our programs are designed to provide relevant information to support people with bleeding disorders and their families with their ability to make informed choices.
Take a look -
Fundraisers and events help us raise awareness and generate crucial resources in support of the bleeding disorders community. Join us at our next event and see how you can get involved.
Find something to do. -
Our grassroots network is an integral part of our larger community. Team up with us and see what a huge difference a little bit of your time can make.
Take action.
News & Announcements
NHF's Wednesday Webinars for April 2021 will feature an array of speakers and topics of interest to both healthcare providers and patients and families with blood disorders alike.
April Webinars
All webinars are from 2:00pm-3:00pm ET.
April 7th, 2021
What is the Burden of Problem Joints with Hemophilia?
Speaker: Paul McLaughlin
April 14th, 2021
WFH Humanitarian Aid Program
Speaker: Assad Haffar
The American Rescue Plan (ARP), signed into law on March 11, 2021, provides new opportunities to get health insurance coverage, and/or to reduce the cost of your premiums. Review your coverage now to make sure you are maximizing your benefits under the new law.
uniQure recently announced the results of a comprehensive investigation into a case of hepatocellular carcinoma (HCC) diagnosed in one patient participating in the phase III HOPE-B pivotal trial of etranacogene dezaparvovec, the company’s investigational gene therapy candidate for individuals with severe and moderately severe hemophilia B.
uniQure recently announced the results of a comprehensive investigation into a case of hepatocellular carcinoma (HCC) diagnosed in one patient participating in the phase III HOPE-B pivotal trial of etranacogene dezaparvovec, the company’s investigational gene therapy candidate for individuals with severe and moderately severe hemophilia B.